Contraception
Volume 77, Issue 1 , Pages 22-29 , January 2008

Subject and clinician experience with the levonorgestrel-releasing intrauterine system

  • Jeffrey T. Jensen

      Affiliations

    • Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR 97239, USA
    • Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    • Corresponding Author InformationCorresponding author. UHN-70 Oregon Health and Science University, Portland, OR 97239, USA. Tel.: +1 503 494 4469; fax: +1 503 494 5083.
    • ,
  • Anita L. Nelson

      Affiliations

    • Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center, Torrance, CA 90502, USA
    • ,
  • Antonio C. Costales

      Affiliations

    • Medical Affairs, Women’s HealthCare, Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ 07470, USA

Received 24 August 2007 ,Revised 3 September 2007 ,Accepted 7 September 2007.

References 

  1. Postlethwaite D, Shaber R, Mancuso V, Flores J, Armstrong MA. Intrauterine contraception: evaluation of clinician practice patterns in Kaiser Permanente Northern California. Contraception. 2007;75(3):177–184
  2. Speroff L, Fritz MA. In: Intrauterine contraception: the IUD. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005;p. 975–995
  3. Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel-and copper-releasing intrauterine devices. Obstet Gynecol. 1991;77:261–264
  4. Mirena® (levonorgestrel intrauterine system) . Prescribing information. Wayne (NJ): Bayer HealthCare Pharmaceuticals Inc; 2007;
  5. Trussell J. Contraceptive efficacy. In:  Hatcher RA,  Trussell J,  Stewart F, et al. editor. Contraceptive technology. 19th revised edition. New York: Ardent Media; 2007;p. 216–217
  6. Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception. 1991;44:473–480
  7. Belsey EM, Farley TMM. The analysis of menstrual bleeding patterns. Contraception. 1988;38:129–156
  8. Backman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol. 2002;99:608–613
  9. Farmer M, Webb A. Intrauterine device insertion-related complications: can they be predicted?. J Fam Plann Reprod Health Care. 2003;29:227–231
  10. Luukkainen T, Allonen H, Haukkamaa M, et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception. 1987;36:169–179
  11. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994;49:56–72
  12. Baveja R, Bichille LK, Coyaji KJ, et al. Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device [LNG], CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Indian Council of Medical Research Task Force on IUD. Contraception. 1989;39:37–52
  13. Sivin I, el Mahgoub S, McCarthy T, et al. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception. 1990;42:361–378
  14. Jensen JT. Noncontraceptive applications of the levonorgestrel intrauterine system. Curr Womens Health Rep. 2002;2:417–422

PII: S0010-7824(07)00422-2

doi: 10.1016/j.contraception.2007.09.006

Contraception
Volume 77, Issue 1 , Pages 22-29 , January 2008

Article Tools

* Image Usage & Resolution